according to Regulation (EC) No. 1907/2006 (REACH)

Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12 date of compilation: 10.02.2017 Version: 2.0 en Revision: 06.04.2022

Replaces version of: 10.02.2017

Version: (1)

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

Product identifier 1.1

Identification of the substance Hygromycin B solution CELLPURE® 50 mg/ml,

sterile

Article number CP12

Registration number (REACH) not relevant (mixture)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses: Laboratory chemical

Laboratory and analytical use

Uses advised against: Do not use for squirting or spraying. Do not use

for products which come into contact with foodstuffs. Do not use for private purposes (house-

hold).

Details of the supplier of the safety data sheet 1.3

Carl Roth GmbH + Co KG Schoemperlenstr, 3-5 D-76185 Karlsruhe Germany

Telephone:+49 (0) 721 - 56 06 0 **Telefax:** +49 (0) 721 - 56 06 149 e-mail: sicherheit@carlroth.de Website: www.carlroth.de

Competent person responsible for the safety data :Department Health, Safety and Environment

sheet:

e-mail (competent person): sicherheit@carlroth.de

1.4 **Emergency telephone number**

SECTION 2: Hazards identification

Classification of the substance or mixture 2.1

Classification according to Regulation (EC) No 1272/2008 (CLP)

Section	Hazard class	Cat- egory	Hazard class and category	Hazard statement
3.10	Acute toxicity (oral)		Acute Tox. 3	H301
3.1D	1D Acute toxicity (dermal)		Acute Tox. 1	H310
3.1I	Acute toxicity (inhal.)		Acute Tox. 1	H330
3.3	Serious eye damage/eye irritation		Eye Dam. 1	H318
3.4R	3.4R Respiratory sensitisation		Resp. Sens. 1	H334
3.45	Skin sensitisation	1	Skin Sens. 1	H317

For full text of abbreviations: see SECTION 16

Page 1 / 18 Malta (en)

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

2.2 Label elements

Labelling according to Regulation (EC) No 1272/2008 (CLP)

Signal word Danger

Pictograms

GHS05, GHS06, GHS08



Hazard statements

H301 Toxic if swallowed

H310+H330 Fatal in contact with skin or if inhaled H317 May cause an allergic skin reaction H318 Causes serious eye damage

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled

Precautionary statements

Precautionary statements - prevention

P261 Avoid breathing mist/vapours/spray

P270 Do not eat, drink or smoke when using this product

P280 Wear protective gloves/eye protection

Precautionary statements - response

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact

lenses, if present and easy to do. Continue rinsing

P309 IF exposed or if you feel unwell:

P310 Immediately call a POISON CENTER/doctor

Hazardous ingredients for labelling: Hygromycin B

Labelling of packages where the contents do not exceed 125 ml

Signal word: Danger

Symbol(s)







H301 Toxic if swallowed.

H310+H330 Fatal in contact with skin or if inhaled.
H317 May cause an allergic skin reaction.
H318 Causes serious eye damage.

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

P261 Avoid breathing mist/vapours/spray.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/eye protection.

P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to

do. Continue rinsing.

P310 Immediately call a POISON CENTER/doctor.

contains: Hygromycin B

Malta (en) Page 2 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

2.3 Other hazards

Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

SECTION 3: Composition/information on ingredients

3.1 Substances

not relevant (mixture)

3.2 Mixtures

Description of the mixture

Name of sub- stance	Identifier	Wt%	Classification acc. to GHS	Pictograms	Notes
Hygromycin B	CAS No 31282-04-9 EC No 250-545-5	5-<7	Acute Tox. 2 / H300 Acute Tox. 1 / H310 Acute Tox. 1 / H330 Eye Dam. 1 / H318 Resp. Sens. 1 / H334 Skin Sens. 1 / H317		

Name of sub- stance	Identifier	Specific Conc. Limits	M-Factors	ATE	Exposure route
Hygromycin B	CAS No 31282-04-9 EC No 250-545-5	-	-	13 ^{mg} / _{kg} 50 ^{mg} / _{kg} 0,002 ^{mg} / _l /4h	oral dermal inhalation: dust/ mist

For full text of abbreviations: see SECTION 16

SECTION 4: First aid measures

4.1 Description of first aid measures



General notes

Take off immediately all contaminated clothing. Self-protection of the first aider.

Following inhalation

Call a physician immediately. If breathing is irregular or stopped, administer artificial respiration.

Following skin contact

After contact with skin, wash immediately with plenty of water. In case of skin reactions, consult a physician.

Following eye contact

In case of contact with eyes flush immediately with plenty of flowing water for 10 to 15 minutes holding eyelids apart and consult an ophthalmologist.

Following ingestion

Rinse mouth immediately and drink plenty of water. Call a physician immediately.

Malta (en) Page 3 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

4.2 Most important symptoms and effects, both acute and delayed

Risk of blindness, Risk of serious damage to eyes, Allergic reactions, Cough, Dyspnoea

4.3 Indication of any immediate medical attention and special treatment needed

none

SECTION 5: Firefighting measures

5.1 Extinguishing media



Suitable extinguishing media

co-ordinate firefighting measures to the fire surroundings water spray, alcohol resistant foam, dry extinguishing powder, BC-powder, carbon dioxide (CO₂)

Unsuitable extinguishing media

water jet

5.2 Special hazards arising from the substance or mixture

None.

Hazardous combustion products

In case of fire may be liberated: Nitrogen oxides (NOx), Carbon monoxide (CO), Carbon dioxide (CO₂)

5.3 Advice for firefighters

In case of fire and/or explosion do not breathe fumes. Fight fire with normal precautions from a reasonable distance. Wear self-contained breathing apparatus. Wear full chemical protective clothing.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures



For non-emergency personnel

Use personal protective equipment as required. Avoid contact with skin, eyes and clothes. Do not breathe vapour/spray.

6.2 Environmental precautions

Keep away from drains, surface and ground water.

6.3 Methods and material for containment and cleaning up

Advice on how to contain a spill

Covering of drains.

Advice on how to clean up a spill

Absorb with liquid-binding material (sand, diatomaceous earth, acid- or universal binding agents).

Other information relating to spills and releases

Place in appropriate containers for disposal. Ventilate affected area.

Malta (en) Page 4 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

6.4 Reference to other sections

Hazardous combustion products: see section 5. Personal protective equipment: see section 8. Incompatible materials: see section 10. Disposal considerations: see section 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Use extractor hood (laboratory). Handle and open container with care. Provision of sufficient ventilation. Clear contaminated areas thoroughly.

Advice on general occupational hygiene

When using do not eat or drink. Thorough skin-cleansing after handling the product.

7.2 Conditions for safe storage, including any incompatibilities

Keep in a cool place.

Incompatible substances or mixtures

Observe hints for combined storage.

Consideration of other advice:

Store locked up.

Ventilation requirements

Keep any substance that emits harmful vapours or gases in a place that allows these to be permanently extracted.

Specific designs for storage rooms or vessels

Recommended storage temperature: 2 – 8 °C

7.3 Specific end use(s)

No information available.

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

National limit values

Occupational exposure limit values (Workplace Exposure Limits)

This information is not available.

8.2 Exposure controls

Individual protection measures (personal protective equipment)

Eye/face protection



Use safety goggle with side protection.

Skin protection



Malta (en) Page 5 / 18

according to Regulation (EC) No. 1907/2006 (REACH)

Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

hand protection

Wear suitable gloves. Chemical protection gloves are suitable, which are tested according to EN 374. Check leak-tightness/impermeability prior to use. For special purposes, it is recommended to check the resistance to chemicals of the protective gloves mentioned above together with the supplier of these gloves. The times are approximate values from measurements at 22 ° C and permanent contact. Increased temperatures due to heated substances, body heat etc. and a reduction of the effective layer thickness by stretching can lead to a considerable reduction of the breakthrough time. If in doubt, contact manufacturer. At an approx. 1.5 times larger / smaller layer thickness, the respective breakthrough time is doubled / halved. The data apply only to the pure substance. When transferred to substance mixtures, they may only be considered as a guide.

type of material

NBR (Nitrile rubber)

material thickness

>0.11 mm

breakthrough times of the glove material

>480 minutes (permeation: level 6)

other protection measures

Take recovery periods for skin regeneration. Preventive skin protection (barrier creams/ointments) is recommended.

Respiratory protection





Respiratory protection necessary at: Aerosol or mist formation.

Environmental exposure controls

Keep away from drains, surface and ground water.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state

Colour colourless - light yellow

Odour faintly perceptible

Melting point/freezing point not determined

Boiling point or initial boiling point and boiling 100 °C

range

Flammability

non-combustible Lower and upper explosion limit not determined

not determined Flash point Auto-ignition temperature not determined

not relevant Decomposition temperature

pH (value) 6 - 8

Kinematic viscosity not determined

Page 6 / 18 Malta (en)

according to Regulation (EC) No. 1907/2006 (REACH)

Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

Solubility(ies)

Water solubility miscible in any proportion

Partition coefficient

Partition coefficient n-octanol/water (log value): this information is not available

Vapour pressure 23 hPa at 20 °C

Density and/or relative density

Density $1 \, {\rm g/_{cm^3}}$ at 20 °C

Relative vapour density information on this property is not available

Particle characteristics not relevant (liquid)

Other safety parameters

Oxidising properties none

9.2 Other information

Information with regard to physical hazard classes acc. to GHS (physical hazards): not relevant

Other safety characteristics:

Miscibility completely miscible with water

SECTION 10: Stability and reactivity

10.1 Reactivity

This material is not reactive under normal ambient conditions.

10.2 Chemical stability

The material is stable under normal ambient and anticipated storage and handling conditions of temperature and pressure.

10.3 Possibility of hazardous reactions

Violent reaction with: strong oxidiser

10.4 Conditions to avoid

There are no specific conditions known which have to be avoided.

10.5 Incompatible materials

There is no additional information.

10.6 Hazardous decomposition products

Hazardous combustion products: see section 5.

Malta (en) Page 7 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Test data are not available for the complete mixture.

Classification procedure

The method for classification of the mixture is based on ingredients of the mixture (additivity formula).

Classification according to GHS (1272/2008/EC, CLP)

Acute toxicity

Toxic if swallowed. Fatal in contact with skin. Fatal if inhaled.

Acute toxicity estimate (ATE) of components of the mixture

Name of substance	CAS No	Exposure route	ATE
Hygromycin B	31282-04-9	oral	13 ^{mg} / _{kg}
Hygromycin B	31282-04-9	dermal	50 ^{mg} / _{kg}
Hygromycin B	31282-04-9	inhalation: dust/mist	0,002 ^{mg} / _l /4h

Acute toxicity of components of the mixture

Name of substance	CAS No	Exposure route	Endpoint	Value	Species
Hygromycin B	31282-04-9	oral	LD50	13 ^{mg} / _{kg}	rat
Hygromycin B	31282-04-9	inhalation: dust/mist	LC50	0,002 ^{mg} / _l /4h	rat

Skin corrosion/irritation

Shall not be classified as corrosive/irritant to skin.

Serious eye damage/eye irritation

Causes serious eye damage.

Respiratory or skin sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction.

Germ cell mutagenicity

Shall not be classified as germ cell mutagenic.

Carcinogenicity

Shall not be classified as carcinogenic.

Reproductive toxicity

Shall not be classified as a reproductive toxicant.

Specific target organ toxicity - single exposure

Shall not be classified as a specific target organ toxicant (single exposure).

Specific target organ toxicity - repeated exposure

Shall not be classified as a specific target organ toxicant (repeated exposure).

Malta (en) Page 8 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

Aspiration hazard

Shall not be classified as presenting an aspiration hazard.

Symptoms related to the physical, chemical and toxicological characteristics

If swallowed

Data are not available.

• If in eyes

Causes serious eye damage, risk of blindness

• If inhaled

May produce an allergic reaction, cough, Dyspnoea

• If on skin

May produce an allergic reaction, pruritis, localised redness

Other information

Symptoms can occur only after several hours

11.2 Endocrine disrupting properties

None of the ingredients are listed.

11.3 Information on other hazards

There is no additional information.

SECTION 12: Ecological information

12.1 Toxicity

Shall not be classified as hazardous to the aquatic environment.

Biodegradation

Data are not available.

12.2 Process of degradability

Data are not available.

12.3 Bioaccumulative potential

Data are not available.

Bioaccumulative potential of components of the mixture

Name of substance	CAS No	BCF	Log KOW	BOD5/COD
Hygromycin B	31282-04-9		-10,24	

12.4 Mobility in soil

Data are not available.

12.5 Results of PBT and vPvB assessment

Data are not available.

12.6 Endocrine disrupting properties

None of the ingredients are listed.

12.7 Other adverse effects

Data are not available.

Malta (en) Page 9 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

SECTION 13: Disposal considerations

13.1 Waste treatment methods



This material and its container must be disposed of as hazardous waste. Dispose of contents/container in accordance with local/regional/national/international regulations.

Sewage disposal-relevant information

Do not empty into drains.

Waste treatment of containers/packagings

It is a dangerous waste; only packagings which are approved (e.g. acc. to ADR) may be used.

13.2 Relevant provisions relating to waste

The allocation of waste identity numbers/waste descriptions must be carried out according to the EEC, specific to the industry and process. Waste catalogue ordinance (Germany).

13.3 Remarks

Waste shall be separated into the categories that can be handled separately by the local or national waste management facilities. Please consider the relevant national or regional provisions.

SECTION 14: Transport information

14.1 UN number or ID number

ADR UN 3172 IMDG-Code UN 3172 ICAO-TI UN 3172

14.2 UN proper shipping name

ADR TOXINS, EXTRACTED FROM LIVING SOURCES, LI-

QUID, N.O.S.

IMDG-Code TOXINS, EXTRACTED FROM LIVING SOURCES, LI-

QUID, N.O.S.

ICAO-TI Toxins, extracted from living sources, liquid,

n.o.s.

Technical name (hazardous ingredients) Hygromycin B

14.3 Transport hazard class(es)

ADR 6.1 IMDG-Code 6.1 ICAO-TI 6.1

14.4 Packing group

ADR II IMDG-Code II ICAO-TI II

Malta (en) Page 10 / 18

according to Regulation (EC) No. 1907/2006 (REACH)

ROTH

Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

14.5 Environmental hazards non-environmentally hazardous acc. to the dan-

gerous goods regulations

14.6 Special precautions for user

Provisions for dangerous goods (ADR) should be complied within the premises.

14.7 Maritime transport in bulk according to IMO instruments

The cargo is not intended to be carried in bulk.

14.8 Information for each of the UN Model Regulations

Transport of dangerous goods by road, rail and inland waterway (ADR/RID/ADN) - Additional information

Proper shipping name TOXINS, EXTRACTED FROM LIVING SOURCES, LI-

QUID, N.O.S.

Particulars in the transport document UN3172, TOXINS, EXTRACTED FROM LIVING

UN3172, TOXINS, EXTRACTED FROM LIVING SOURCES, LIQUID, N.O.S., (contains: Hygromycin

B), 6.1, II, (D/E)

Classification code T1

Danger label(s) 6.1



Special provisions (SP) 210, 274, 802(ADN)

Excepted quantities (EQ) E4

Limited quantities (LQ) 100 ml

Transport category (TC) 2
Tunnel restriction code (TRC) D/E
Hazard identification No 60

International Maritime Dangerous Goods Code (IMDG) - Additional information

Proper shipping name TOXINS, EXTRACTED FROM LIVING SOURCES, LI-

QUID, N.O.S.

Particulars in the shipper's declaration UN3172, TOXINS, EXTRACTED FROM LIVING

SOURCES, LIQUID, N.O.S., (contains: Hygromycin

B), 6.1, II

Marine pollutant

Danger label(s) 6.1



Special provisions (SP) 210, 274

Excepted quantities (EQ) E4

Limited quantities (LQ) 100 mL

EmS F-A, S-A

Stowage category B

Malta (en) Page 11 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

International Civil Aviation Organization (ICAO-IATA/DGR) - Additional information

Proper shipping name Toxins, extracted from living sources, liquid,

n.o.s.

Particulars in the shipper's declaration UN3172, Toxins, extracted from living sources, li-

quid, n.o.s., (contains: Hygromycin B), 6.1, II

Danger label(s) 6.1

Special provisions (SP) A3, A43

Excepted quantities (EQ) **E4** Limited quantities (LQ) 1 L

SECTION 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture Relevant provisions of the European Union (EU)

Restrictions according to REACH, Annex XVII

Dangerous substances with restrictions (REACH, Annex XVII)

Name of substance	Name acc. to inventory	CAS No	Restriction	No
Hygromycin B solution	this product meets the criteria for classification in accordance with Reg- ulation No 1272/2008/EC		R3	3
Hygromycin B	substances in tattoo inks and permanent make-up		R75	75

Legend

1. Shall not be used in:

- ornamental articles intended to produce light or colour effects by means of different phases, for example in ornamental lamps and ashtrays,

- tricks and jokes,

games for one or more participants, or any article intended to be used as such, even with ornamental aspects,

2. Articles not complying with paragraph 1 shall not be placed on the market.

3. Shall not be placed on the market if they contain a colouring agent, unless required for fiscal reasons, or perfume, or both, if they

— can be used as fuel in decorative oil lamps for supply to the general public, and — present an aspiration hazard and are labelled with H304.

- 4. Decorative oil lamps for supply to the general public shall not be placed on the market unless they conform to the European Standard on Decorative oil lamps (EN 14059) adopted by the European Committee for Standardisation
- (CEN).

 5. Without prejudice to the implementation of other Union provisions relating to the classification, labelling and packaging of substances and mixtures, suppliers shall ensure, before the placing on the market, that the following requirements are met:

 1. The last with 1204 intended for supply to the general public are visibly, legibly and indelibly marked as

ments are met:

(a) lamp oils, labelled with H304, intended for supply to the general public are visibly, legibly and indelibly marked as follows: "Keep lamps filled with this liquid out of the reach of children"; and, by 1 December 2010, "Just a sip of lamp oil – or even sucking the wick of lamps – may lead to life-threatening lung damage";

(b) grill lighter fluids, labelled with H304, intended for supply to the general public are legibly and indelibly marked by 1 December 2010 as follows: 'Just a sip of grill lighter fluid may lead to life threatening lung damage';

(c) lamps oils and grill lighters, labelled with H304, intended for supply to the general public are packaged in black parameter and exceedings 1 litro by 1 December 2010."

opaque containers not exceeding 1 litre by 1 December 2010.';

Page 12 / 18 Malta (en)

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

Legend

1. Shall not be placed on the market in mixtures for use for tattooing purposes, and mixtures containing any such substances shall not be used for tattooing purposes, after 4 January 2022 if the substance or substances in question is or are present in the following circumstances:

(a) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as carcinogen category

1A, 1B or 2, or germ cell mutagen category 1A, 1B or 2, the substance is present in the mixture in a concentration equal to or greater than 0,00005 % by weight; (b) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as reproductive toxicant category 1A, 1B or 2, the substance is present in the mixture in a concentration equal to or greater than 0,001 % by

(c) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as skin sensitiser category 1, 1A or 1B, the substance is present in the mixture in a concentration equal to or greater than 0,001 % by weight;

(d) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as skin corrosive category 1, 1A, 1B or 1C or skin irritant category 2, or as serious eye damage category 1 or eye irritant category 2, the substance is present in the mixture in a concentration equal to or greater than:

(i) 0,1 % by weight, if the substance is used solely as a pH regulator

(ií) 0,01 % by weight, in all other cases;

(e) in the case of a substance listed in Annex II to Regulation (EC) No 1223/2009 (*1), the substance is present in the

mixture in a concentration equal to or greater than 0,00005 % by weight;

(f) in the case of a substance for which a condition of one or more of the following kinds is specified in column g (Product type, Body parts) of the table in Annex IV to Regulation (EC) No 1223/2009, the substance is present in the mixture in a concentration equal to or greater than 0,00005 % by weight:

(i) "Rinse-off products";
(ii) "Not to be used in products applied on mucous membranes";
(iii) "Not to be used in eye products";

(g) in the case of a substance for which a condition is specified in column h (Maximum concentration in ready for use preparation) or column i (Other) of the table in Annex IV to Regulation (EC) No 1223/2009, the substance is present in the mixture in a concentration, or in some other way, that does not accord with the condition specified in that column; (h) in the case of a substance listed in Appendix 13 to this Annex, the substance is present in the mixture in a concen-

(n) in the case of a substance listed in Appendix 13 to this Annex, the substance is present in the mixture in a concentration equal to or greater than the concentration limit specified for that substance in that Appendix.

2. For the purposes of this entry use of a mixture "for tattooing purposes" means injection or introduction of the mixture into a person's skin, mucous membrane or eyeball, by any process or procedure (including procedures commonly referred to as permanent make-up, cosmetic tattooing, micro-blading and micro-pigmentation), with the aim of making a mark or design on his or her body.

3. If a substance not listed in Appendix 13 falls within more than one of points (a) to (g) of paragraph 1, the strictest concentration limit laid down in the points in question shall apply to that substance. If a substance listed in Appendix 13 also falls within one or more of points (a) to (g) of paragraph 1, the concentration limit laid down in point (h) of paragraph 1 shall apply to that substance.

as also falls within one of more of points (a) to (g) of paragraph 1, the concentration limit faid down in point (ii) of paragraph 1 shall apply to that substance.

4. By way of derogation, paragraph 1 shall not apply to the following substances until 4 January 2023:
(a) Pigment Blue 15:3 (CI 74160, EC No 205-685-1, CAS No 147-14-8);
(b) Pigment Green 7 (CI 74260, EC No 215-524-7, CAS No 1328-53-6).

5. If Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended after 4 January 2021 to classify or re-classify a substance such that the substance then becomes caught by point (a), (b), (c) or (d) of paragraph 1 of this entry, or such that it then falls within a different one of those points from the one within which it fell previously, and the date of application of that now or revised classification in fifty the date referred to in paragraph 1 or as the case may be paragraph. plication of that new or revised classification is after the date referred to in paragraph 1 or, as the case may be, paragraph 4 of this entry, that amendment shall, for the purposes of applying this entry to that substance, be treated as taking effect on the date of application of that new or revised classification.

6. If Annex II or Annex IV to Regulation (EC) No 1223/2009 is amended after 4 January 2021 to list or change the listing of a substance such that the substance then becomes caught by point (e), (f) or (g) of paragraph 1 of this entry, or such that it then falls within a different one of those points from the one within which it fell previously, and the

amendment takes effect after the date referred to in paragraph 1 or, as the case may be, paragraph 4 of this entry, that amendment shall, for the purposes of applying this entry to that substance, be treated as taking effect from the date falling 18 months after entry into force of the act by which that amendment was made.

7. Suppliers placing a mixture on the market for use for tattooing purposes shall ensure that, after 4 January 2022, the mixture is marked with the following information:

(a) the statement "Mixture for use in tattoos or permanent make-up";

(a) the statement "Mixture for use in tattoos or permanent make-up";
(b) a reference number to uniquely identify the batch;
(c) the list of ingredients in accordance with the nomenclature established in the glossary of common ingredient names pursuant to Article 33 of Regulation (EC) No 1223/2009, or in the absence of a common ingredient name, the IUPAC name. In the absence of a common ingredient name or IUPAC name, the CAS and EC number. Ingredients shall be listed in descending order by weight or volume of the ingredients at the time of formulation. "Ingredient" means any substance added during the process of formulation and present in the mixture for use for tattooing purposes. Impurities shall not be regarded as ingredients. If the name of a substance, used as ingredient within the meaning of this entry, is already required to be stated on the label in accordance with Regulation (EC) No 1272/2008, that ingredient does not need to be marked in accordance with this Regulation;
(d) the additional statement "pH regulator" for substances falling under point (d)(i) of paragraph 1;
(e) the statement "Contains nickel. Can cause allergic reactions." if the mixture contains nickel below the concentration limit specified in Appendix 13;

tion limit specified in Appendix 13

(f) the statement "Contains chromium (VI). Can cause allergic reactions." if the mixture contains chromium (VI) below

the concentration limit specified in Appendix 13; (g) safety instructions for use insofar as they are not already required to be stated on the label by Regulation (EC) No 1272/2008.

The information shall be clearly visible, easily legible and marked in a way that is indelible.

The information shall be written in the official language(s) of the Member State(s) where the mixture is placed on the market, unless the Member State(s) concerned provide(s) otherwise.

Where necessary because of the size of the package, the information listed in the first subparagraph, except for point (a), shall be included instead in the instructions for use.

Before using a mixture for tattooing purposes, the person using the mixture shall provide the person undergoing the procedure with the information marked on the package or included in the instructions for use pursuant to this paragraph. 8. Mixtures that do not contain the statement "Mixture for use in tattoos or permanent make-up" shall not be used for

tattooing purposes.

Page 13 / 18 Malta (en)

according to Regulation (EC) No. 1907/2006 (REACH)

ROTH

Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

Legend

9. This entry does not apply to substances that are gases at temperature of 20 $^{\circ}$ C and pressure of 101,3 kPa, or generate a vapour pressure of more than 300 kPa at temperature of 50 $^{\circ}$ C, with the exception of formaldehyde (CAS No 50-00-0, EC No 200-001-8).

10. This entry does not apply to the placing on the market of a mixture for use for tattooing purposes, or to the use of a mixture for tattooing purposes, when placed on the market exclusively as a medical device or an accessory to a medical device, within the meaning of Regulation (EU) 2017/745, or when used exclusively as a medical device or an accessory to a medical device, within the same meaning. Where the placing on the market or use may not be exclusively as a medical device or an accessory to a medical device, the requirements of Regulation (EU) 2017/745 and of this Regulation shall apply cumulatively.

List of substances subject to authorisation (REACH, Annex XIV)/SVHC - candidate list

None of the ingredients are listed.

Seveso Directive

2012/	2012/18/EU (Seveso III)							
No	Dangerous substance/hazard categories		(tonnes) for the ap- and upper-tier re- ments	Notes				
H1	acute toxic (cat. 1)	5	20	40)				

Notation

40) Category 1, all exposure routes

Deco-Paint Directive

VOC content	0 % 0 ⁹ / _I
-------------	--------------------------------------

Industrial Emissions Directive (IED)

VOC content	0 %
VOC content (Water content was discounted)	0 ^g / _l

Directive on the restriction of the use of certain hazardous substances in electrical and electronic equipment (RoHS)

none of the ingredients are listed

Regulation concerning the establishment of a European Pollutant Release and Transfer Register (PRTR)

none of the ingredients are listed

Water Framework Directive (WFD)

none of the ingredients are listed

Regulation on the marketing and use of explosives precursors

none of the ingredients are listed

Regulation on drug precursors

none of the ingredients are listed

Regulation on substances that deplete the ozone layer (ODS)

none of the ingredients are listed

Regulation concerning the export and import of hazardous chemicals (PIC)

none of the ingredients are listed

Regulation on persistent organic pollutants (POP)

Malta (en) Page 14 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

none of the ingredients are listed

Other information

Directive 94/33/EC on the protection of young people at work. Observe employment restrictions under the Maternity Protection Directive (92/85/EEC) for expectant or nursing mothers.

National inventories

Country	Inventory	Status
AU	AICS	not all ingredients are listed
CA	DSL	not all ingredients are listed
CN	IECSC	all ingredients are listed
EU	ECSI	all ingredients are listed
JP	CSCL-ENCS	not all ingredients are listed
KR	KECI	not all ingredients are listed
MX	INSQ	not all ingredients are listed
NZ	NZIoC	all ingredients are listed
PH	PICCS	not all ingredients are listed
TW	TCSI	all ingredients are listed
US	TSCA	not all ingredients are listed

Legend

Australian Inventory of Chemical Substances List of Existing and New Chemical Substances (CSCL-ENCS) AICS CSCL-ENCS

DSL ECSI

IECSC

List of Existing and New Chemical Substances (CSCL-ENCS)
Domestic Substances List (DSL)
EC Substance Inventory (EINECS, ELINCS, NLP)
Inventory of Existing Chemical Substances Produced or Imported in China
National Inventory of Chemical Substances
Korea Existing Chemicals Inventory
New Zealand Inventory of Chemicals
Philippine Inventory of Chemicals and Chemical Substances (PICCS)
Taiwan Chemical Substance Inventory
Toxic Substance Control Act

Toxic Substance Control Act

15.2 Chemical Safety Assessment

Chemical safety assessments for substances in this mixture were not carried out.

SECTION 16: Other information

Indication of changes (revised safety data sheet)

Alignment to regulation: Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU

Restructuring: section 9, section 14

Section	Former entry (text/value)	Actual entry (text/value)	Safety- relev- ant
2.1		Classification according to Regulation (EC) No 1272/2008 (CLP): change in the listing (table)	yes
2.1	Remarks: For full text of Hazard- and EU Hazard-state- ments: see SECTION 16.		yes

Malta (en) Page 15 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: **CP12**

Section	Former entry (text/value)	Actual entry (text/value)	Safety- relev- ant
2.2		Pictograms: change in the listing (table)	yes
2.2		Precautionary statements - prevention: change in the listing (table)	yes
2.2		Labelling of packages where the contents do not exceed 125 ml: change in the listing (table)	yes
2.3	Other hazards: There is no additional information.	Other hazards	yes
2.3		Results of PBT and vPvB assessment: This mixture does not contain any substances that are assessed to be a PBT or a vPvB.	yes

Abbreviations and acronyms

Abbr.	Descriptions of used abbreviations	
Acute Tox.	Acute toxicity	
ADN	Accord européen relatif au transport international des marchandises dangereuses par voies de naviga- tion intérieures (European Agreement concerning the International Carriage of Dangerous Goods by In- land Waterways)	
ADR	Accord relatif au transport international des marchandises dangereuses par route (Agreement concerning the International Carriage of Dangerous Goods by Road)	
ATE	Acute Toxicity Estimate	
BCF	Bioconcentration factor	
BOD	Biochemical Oxygen Demand	
CAS	Chemical Abstracts Service (service that maintains the most comprehensive list of chemical substances)	
CLP	Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures	
COD	Chemical oxygen demand	
DGR	Dangerous Goods Regulations (see IATA/DGR)	
EC No	The EC Inventory (EINECS, ELINCS and the NLP-list) is the source for the seven-digit EC number, an identifier of substances commercially available within the EU (European Union)	
EINECS	European Inventory of Existing Commercial Chemical Substances	
ELINCS	European List of Notified Chemical Substances	
EmS	Emergency Schedule	
Eye Dam.	Seriously damaging to the eye	
Eye Irrit.	Irritant to the eye	
GHS	"Globally Harmonized System of Classification and Labelling of Chemicals" developed by the United Nations	
IATA	International Air Transport Association	
IATA/DGR	Dangerous Goods Regulations (DGR) for the air transport (IATA)	
ICAO	International Civil Aviation Organization	
ICAO-TI	Technical instructions for the safe transport of dangerous goods by air	

Malta (en) Page 16 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

Abbr.	Descriptions of used abbreviations
IMDG	International Maritime Dangerous Goods Code
IMDG-Code	International Maritime Dangerous Goods Code
index No	The Index number is the identification code given to the substance in Part 3 of Annex VI to Regulation (EC) No 1272/2008
LC50	Lethal Concentration 50%: the LC50 corresponds to the concentration of a tested substance causing 50 % lethality during a specified time interval
LD50	Lethal Dose 50 %: the LD50 corresponds to the dose of a tested substance causing 50 % lethality during a specified time interval
log KOW	n-Octanol/water
NLP	No-Longer Polymer
PBT	Persistent, Bioaccumulative and Toxic
REACH	Registration, Evaluation, Authorisation and Restriction of Chemicals
Resp. Sens.	Respiratory sensitisation
RID	Règlement concernant le transport International ferroviaire des marchandises Dangereuses (Regulations concerning the International carriage of Dangerous goods by Rail)
Skin Sens.	Skin sensitisation
SVHC	Substance of Very High Concern
VOC	Volatile Organic Compounds
vPvB	Very Persistent and very Bioaccumulative

Key literature references and sources for data

Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures. Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU.

Agreement concerning the International Carriage of Dangerous Goods by Road (ADR). International Maritime Dangerous Goods Code (IMDG). Dangerous Goods Regulations (DGR) for the air transport (IATA).

Classification procedure

Physical and chemical properties. The classification is based on tested mixture. Health hazards. Environmental hazards. The method for classification of the mixture is based on ingredients of the mixture (additivity formula).

List of relevant phrases (code and full text as stated in section 2 and 3)

Code	Text
H300	Fatal if swallowed.
H301	Toxic if swallowed.
H310	Fatal in contact with skin.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H330	Fatal if inhaled.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Malta (en) Page 17 / 18

according to Regulation (EC) No. 1907/2006 (REACH)



Hygromycin B solution CELLPURE® 50 mg/ml, sterile

article number: CP12

Disclaimer

This information is based upon the present state of our knowledge. This SDS has been compiled and is solely intended for this product.

Malta (en) Page 18 / 18